3.45
price up icon1.02%   0.03
after-market Handel nachbörslich: 3.45
loading
Schlusskurs vom Vortag:
$3.42
Offen:
$3.41
24-Stunden-Volumen:
537.75K
Relative Volume:
0.98
Marktkapitalisierung:
$154.10M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-32.74M
KGV:
-4.2073
EPS:
-0.82
Netto-Cashflow:
$-24.89M
1W Leistung:
-0.43%
1M Leistung:
-34.69%
6M Leistung:
-70.79%
1J Leistung:
-66.23%
1-Tages-Spanne:
Value
$3.35
$3.48
1-Wochen-Bereich:
Value
$3.35
$3.56
52-Wochen-Spanne:
Value
$3.18
$16.94

Third Harmonic Bio Inc Stock (THRD) Company Profile

Name
Firmenname
Third Harmonic Bio Inc
Name
Telefon
(209) 727-2457
Name
Adresse
1700 MONTGOMERY STREET, SAN FRANCISCO
Name
Mitarbeiter
51
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
THRD's Discussions on Twitter

Vergleichen Sie THRD mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
THRD
Third Harmonic Bio Inc
3.45 154.10M 0 -32.74M -24.89M -0.82
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
479.79 121.85B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
698.74 76.83B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
624.67 37.96B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
246.75 30.69B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beone Medicines Ltd Adr
271.80 29.71B 3.32B -860.46M -1.04B -8.32

Third Harmonic Bio Inc Stock (THRD) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-02-12 Herabstufung Morgan Stanley Overweight → Equal-Weight
2025-02-11 Herabstufung Raymond James Outperform → Mkt Perform
2024-08-09 Hochstufung Morgan Stanley Equal-Weight → Overweight
2024-06-18 Eingeleitet Stifel Buy
2024-06-07 Eingeleitet Raymond James Outperform
2022-12-16 Herabstufung Jefferies Buy → Hold
2022-12-15 Herabstufung Morgan Stanley Overweight → Equal-Weight
2022-10-10 Eingeleitet Cowen Outperform
2022-10-10 Eingeleitet Jefferies Buy
2022-10-10 Eingeleitet Morgan Stanley Overweight
Alle ansehen

Third Harmonic Bio Inc Aktie (THRD) Neueste Nachrichten

pulisher
12:52 PM

Layoff Tracker: BMS’ Latest Cuts in New Jersey Will Affect 223 Employees - BioSpace

12:52 PM
pulisher
Feb 23, 2025

Companies Like Third Harmonic Bio (NASDAQ:THRD) Are In A Position To Invest In Growth - Yahoo Finance

Feb 23, 2025
pulisher
Feb 15, 2025

Third Harmonic Bio downgraded to Market Perform from Outperform at Raymond James - MSN

Feb 15, 2025
pulisher
Feb 14, 2025

Third Harmonic Bio progresses THB335 to Phase 2 trial - MSN

Feb 14, 2025
pulisher
Feb 14, 2025

Third Harmonic Bio, Inc. (THRD) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance

Feb 14, 2025
pulisher
Feb 14, 2025

Down -39.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Third Harmonic Bio, Inc. (THRD) - Nasdaq

Feb 14, 2025
pulisher
Feb 14, 2025

Third Harmonic stock rating cut by Raymond James - MSN

Feb 14, 2025
pulisher
Feb 12, 2025

Third Harmonic Bio Initiates Strategic Review, Lays Off 50% Staff Citing Competitive Landscape - AOL

Feb 12, 2025
pulisher
Feb 12, 2025

Raymond James downgrades Third Harmonic Bio on uncertainty for only asset - MSN

Feb 12, 2025
pulisher
Feb 12, 2025

Morgan Stanley Downgrades Third Harmonic Bio to Equalweight From Overweight, Cuts Price Target to $5 From $20 - Marketscreener.com

Feb 12, 2025
pulisher
Feb 12, 2025

Third Harmonic and Inventiva slash workforces - The Pharma Letter

Feb 12, 2025
pulisher
Feb 12, 2025

Third Harmonic Bio progresses THB335 to Phase 2 trial By Investing.com - Investing.com Nigeria

Feb 12, 2025
pulisher
Feb 11, 2025

Morgan Stanley cuts Third Harmonic stock rating amid uncertainty - MSN

Feb 11, 2025
pulisher
Feb 11, 2025

Finance Watch: Third Harmonic, Q32 Bio Cut Jobs To Focus On Lead Assets - News & Insights

Feb 11, 2025
pulisher
Feb 11, 2025

Morgan Stanley cuts Third Harmonic stock rating amid uncertainty By Investing.com - Investing.com Canada

Feb 11, 2025
pulisher
Feb 11, 2025

Third Harmonic Bio, Inc.: Hold Rating Amid Strategic Uncertainty and Safety Concerns - TipRanks

Feb 11, 2025
pulisher
Feb 11, 2025

12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga

Feb 11, 2025
pulisher
Feb 11, 2025

Optimistic Buy Rating for Third Harmonic Bio Amid Promising Trial Results and Safety Concerns - TipRanks

Feb 11, 2025
pulisher
Feb 11, 2025

Third Harmonic Bio Inc (THRD) Stock: A Year of Stock Market Dynamics - The InvestChronicle

Feb 11, 2025
pulisher
Feb 11, 2025

Stock market news: Fluence Energy -47.86%, Columbus McKinnon -40.83% among biggest losers during midday trading - Business Upturn

Feb 11, 2025
pulisher
Feb 11, 2025

Third Harmonic stock rating cut by Raymond James By Investing.com - Investing.com South Africa

Feb 11, 2025
pulisher
Feb 11, 2025

Merck KGaA pursuing Springworks; BridgeBio wins EU drug OK - BioPharma Dive

Feb 11, 2025
pulisher
Feb 11, 2025

Third Harmonic Bio Shares Slump After 50% Workforce Cut, Strategic Review Set -February 11, 2025 at 10:34 am EST - Marketscreener.com

Feb 11, 2025
pulisher
Feb 11, 2025

Stock market today: Fluence Energy -46.44%, Columbus McKinnon -42.05% among biggest losers in early trading - Business Upturn

Feb 11, 2025
pulisher
Feb 11, 2025

Third Harmonic Bio, Inc. Announces Restructuring Plan - TipRanks

Feb 11, 2025
pulisher
Feb 11, 2025

Third Harmonic Bio stock tumbles after clinical trial results - Investing.com

Feb 11, 2025
pulisher
Feb 11, 2025

Hain Celestial Group Inc’s Mixed Bag: Down -43.22% in 6 Months, Down -22.12% in 30 Days - The InvestChronicle

Feb 11, 2025
pulisher
Feb 11, 2025

Third Harmonic Bio stock tumbles after clinical trial results By Investing.com - Investing.com South Africa

Feb 11, 2025
pulisher
Feb 11, 2025

Third Harmonic halves headcount to take urticaria drug into phase 2 despite side effects - Fierce Biotech

Feb 11, 2025
pulisher
Feb 11, 2025

Third Harmonic Bio Announces Phase 1 Clinical Results for THB335 and Provides Corporate Strategic Update - The Manila Times

Feb 11, 2025
pulisher
Feb 11, 2025

Third Harmonic Bio Announces Phase 1 Clinical Results for THB335 and Provides Corporate - The Bakersfield Californian

Feb 11, 2025
pulisher
Feb 10, 2025

Third Harmonic Bio Announces Phase 1 Clinical Results for THB335 -February 11, 2025 at 07:00 am EST - Marketscreener.com

Feb 10, 2025
pulisher
Feb 09, 2025

(THRD) Investment Analysis - Stock Traders Daily

Feb 09, 2025
pulisher
Feb 08, 2025

Spruce Biosciences Inc (NASDAQ: SPRB) Stock Has Gained 4.05% Over The Month – Is There Room For Growth? - Marketing Sentinel

Feb 08, 2025
pulisher
Feb 08, 2025

Should You Expect Akero Therapeutics Inc (NASDAQ:AKRO) To Recover From Its 70.02% Gain From Highs? - Marketing Sentinel

Feb 08, 2025
pulisher
Feb 08, 2025

Five Point Holdings LLC (NYSE: FPH): Can The Stock Still Lose Despite An 54.23% YTD Gain? - Marketing Sentinel

Feb 08, 2025
pulisher
Feb 08, 2025

After Falling -7.79% During The Past Week, Should You Still Buy Third Harmonic Bio Inc (NASDAQ: THRD)? - Marketing Sentinel

Feb 08, 2025
pulisher
Feb 07, 2025

Analytical Overview: Orasure Technologies Inc (OSUR)’s Ratios Tell a Financial Story - The Dwinnex

Feb 07, 2025
pulisher
Feb 07, 2025

Balance Sheet Insights: Chart Industries Inc (GTLS)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex

Feb 07, 2025
pulisher
Feb 07, 2025

Ratios Reveal: Breaking Down Third Harmonic Bio Inc (THRD)’s Financial Health - The Dwinnex

Feb 07, 2025

Finanzdaten der Third Harmonic Bio Inc-Aktie (THRD)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Third Harmonic Bio Inc-Aktie (THRD) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Conner Edward R.
Chief Medical Officer
Nov 08 '24
Sale
15.00
2,117
31,755
0
BVF PARTNERS L P/IL
See Explanation of Responses
Oct 29 '24
Sale
14.30
1,000,000
14,300,000
176,692
Conner Edward R.
Chief Medical Officer
Oct 28 '24
Option Exercise
4.20
2,673
11,227
2,673
Conner Edward R.
Chief Medical Officer
Oct 28 '24
Sale
15.00
2,673
40,095
0
$81.55
price up icon 2.95%
$22.68
price down icon 0.31%
$33.64
price up icon 0.63%
$319.86
price down icon 1.18%
$113.03
price up icon 3.89%
biotechnology ONC
$271.80
price down icon 2.56%
Kapitalisierung:     |  Volumen (24h):